TY - JOUR
T1 - The 2018 assisi think tank meeting on breast cancer
T2 - International expert panel white paper
AU - Arenas, Meritxell
AU - Selek, Ugur
AU - Kaidar-Person, Orit
AU - Perrucci, Elisabetta
AU - Montero Luis, Angel
AU - Boersma, Liesbeth
AU - Coles, Charlotte
AU - Offersen, Birgitte
AU - Meattini, Icro
AU - Bölükbaşı, Yasemin
AU - Leonardi, Maria Cristina
AU - Pfeffer, Raphael
AU - Cutuli, Bruno
AU - Vidali, Cristiana
AU - Franco, Pierfrancesco
AU - Kouloulias, Vassilis
AU - Masiello, Valeria
AU - Rivera, Sofia
AU - Bourgier, Céline
AU - Ciabattoni, Antonella
AU - Lancellotta, Valentina
AU - Trigo, Lurdes
AU - Valentini, Vincenzo
AU - Poortmans, Philip
AU - Aristei, Cynthia
N1 - Funding Information:
Currently recruiting patients are 2 randomized U.S. clinical trials: Alliance 11202 and NSABP-B51. In the UK, the ATNEC randomised controlled trial (RCT) is now funded by the National Institute of Health Research Health Technology and Assessment Programme. In the Netherlands, the RaPChem study is on-going.
Funding Information:
The authors declare that they have no conflict of interest. Doctor Charlotte Coles is supported by the National Institute of Health Research (NIHR) Research Professorship and Cambridge Biomedical Research Centre . Dr Ugur Selek is an Accuray Advisory Board.
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - We report on the second Assisi Think Tank Meeting (ATTM) on breast cancer which was held under the auspices of the European Society for RadioTherapy & Oncology (ESTRO). In discussing in-depth current evidence and practice it was designed to identify grey areas in diverse forms of the disease. It aimed at addressing uncertainties and proposing future trials to improve patient care. Before the meeting, three key topics were selected: 1) primary systemic therapy, mastectomy, breast reconstruction and post-mastectomy radiation therapy, 2) therapeutic options in ductal carcinoma in situ, and 3) therapy de-escalation in early stage breast cancer. Clinical practice in these areas was investigated by means of an online questionnaire. The time lapse period between the survey and the meeting was used to review the literature and on-going clinical trials. At the ATTM both were discussed in depth and research protocols were proposed.
AB - We report on the second Assisi Think Tank Meeting (ATTM) on breast cancer which was held under the auspices of the European Society for RadioTherapy & Oncology (ESTRO). In discussing in-depth current evidence and practice it was designed to identify grey areas in diverse forms of the disease. It aimed at addressing uncertainties and proposing future trials to improve patient care. Before the meeting, three key topics were selected: 1) primary systemic therapy, mastectomy, breast reconstruction and post-mastectomy radiation therapy, 2) therapeutic options in ductal carcinoma in situ, and 3) therapy de-escalation in early stage breast cancer. Clinical practice in these areas was investigated by means of an online questionnaire. The time lapse period between the survey and the meeting was used to review the literature and on-going clinical trials. At the ATTM both were discussed in depth and research protocols were proposed.
KW - Breast cancer
KW - Breast reconstruction
KW - De-escalating therapy
KW - Ductal carcinoma in situ
KW - Hypofractionation
KW - Neoadjuvant chemotherapy
KW - Partial breast irradiation
KW - Post-mastectomy radiation therapy
KW - Radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85085021790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085021790&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.102967
DO - 10.1016/j.critrevonc.2020.102967
M3 - Review article
C2 - 32450277
AN - SCOPUS:85085021790
VL - 151
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
M1 - 102967
ER -